How should we integrate and incorporate ctDNA profiling with tissue-based whole exome NGS, including longitudinal biopsies? When are these two tests potentially complementary?

How should we integrate and incorporate ctDNA profiling with tissue-based whole exome NGS, including longitudinal biopsies? When are these two tests potentially complementary?

Based on the evidence available, how should we be integrating and incorporating ctDNA profiling with tissue-based whole exome NGS, including longitudinal biopsies? In what settings, patients, and situations are these two tests potentially complementary? Can you use lung cancer mutational profiles, validation data, and resistance signatures as an example?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Samuel Klempner, MD

Samuel Klempner, MD

Director of Precision Medicine
The Angeles Clinic and Research Institute
Cedars-Sinai Medical Center
Los Angeles, CA